ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti-TIM3 Immunotherapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Despite advancements in immune checkpoint blockade (ICB) therapy, breast cancer shows limited response to anti-PD1/PD-L1 treatments, emphasizing the need for alternative ICB targets. Here, we reveal that endocrine therapeutics, specifically tamoxifen, create an immunosuppressive yet primed tumor microenvironment conducive to anti-TIM3 immunotherapy. Tamoxifen induces mitochondrial DNA damage and disrupts the RACK7/KDM5C histone demethylase complex, resulting in STING accumulation and activation of the type I interferon (IFN-I) pathway, thereby fostering an immunogenic tumor microenvironment. However, tamoxifen also elevates CEACAM1 expression via a RACK7/KDM5C axis, driving T-cell exhaustion and limiting tumor elimination. This dual effect of tamoxifen - promoting STING-mediated immunogenicity while upregulating CEACAM1 expression - shapes the tumor-immune microenvironment in both ER-positive and ER-negative tumors. Notably, combining anti-TIM3 immunotherapy with tamoxifen mitigates its immunosuppressive effects, potentially enhancing ICB efficacy. Our findings highlight the therapeutic potential of integrating anti-TIM3 immunotherapy with endocrine therapy to improve outcomes for breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.